Othman Al-Sawaf

29PUBLICATIONS
62CO-AUTHORS
Predictive and prognostic markersReproductive medicine not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplications in health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Jul 07, 2026
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

|Jun 12, 2026
Remission with residuals, but no cure.

|Apr 14, 2026
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Nadine Kutsch, Rudy Ligtvoet, Sandra Robrecht

|Mar 17, 2026
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Florian Simon, Rudy Ligtvoet, Moritz Fürstenau

|Jan 13, 2026
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Othman Al-Sawaf, Benjamin N Locher, Friederike Christen

|Dec 08, 2025
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Othman Al-Sawaf, Janina Stumpf, Can Zhang

Pageof 5

Frequent Collaborators

7 joint publications

Florian Simon

6 joint publications

Michael J Hallek

5 joint publications

Carsten Utoft Niemann

5 joint publications

Petra Langerbeins